ALLMedicine™ Juvenile Myelomonocytic Leukemia Center

May 4th, 2022 - WHO Classification and IPSS of Myelodysplastic Syndromes The 2016 World Health Organization (WHO) classification of myelodysplastic syndromes (MDS), [1] as well as the International Prognostic Scoring System (IPSS), are provided below. [2] The 201...

Apr 22nd, 2022 - Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasia that lacks effective targeted chemotherapies. Clinically, JMML manifests as monocytic leukocytosis, splenomegaly with consequential thrombocytopenia. Most common...

Apr 22nd, 2022 - Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busul...

Jan 22nd, 2022 - In pediatric cancer patients, the estimated glomerular filtration rate based on serum cystatin C (CysC) was reported to be suitable for estimating kidney function because of low serum creatinine (Cr) and high serum β2-microglobulin. Recently, howe...

Dec 24th, 2021 - Therapy-related myeloid neoplasms (t-MN) are a distinct subgroup of myeloid malignancies with a poor prognosis that include cases of therapy-related myelodysplastic syndrome (t-MDS), therapy-related myeloproliferative neoplasms (t-MPN) and therapy...

Apr 22nd, 2022 - Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busul...

Aug 10th, 2020 - Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been...

Jul 11th, 2019 - Study Population Pediatric subjects aged 1 month to less than 18 years of age with newly diagnosed conditions of advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML). Length of Study The enrollment period will last fo...

Oct 2nd, 2018 - Hematopoietic stem cell transplantation (HSCT) is the only curative option for most of juvenile myelomonocytic leukemia (JMML). However, persistent disease statute and relapse after HSCT severely influence the long-term overall survival (OS). Rese...

Sep 17th, 2013 - OBJECTIVES: Determine, by a standard approach, the frequency of different FAB subtypes in children with primary myelodysplastic syndromes. Determine the frequency of cytogenetic and molecular abnormalities in these patients. Determine the survival...

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

Apr 21st, 2017 - BY JEREMY UDKOFF AND CATALINA MATIZ, MD Juvenile xanthogranuloma (JXG), a non–Langerhans cell histiocytosis, is a common pediatric tumor that most commonly presents either at birth, in infants, or in young children – with the majority of cases occ.

Oct 9th, 2015 - Colony of iPSCs Image from the Salk Institute Researchers have used induced pluripotent stem cells (iPSCs) to model juvenile myelomonocytic leukemia (JMML) and gain new insight into the disease. The team noted that somatic PTPN11 mutations are kno.

Oct 6th, 2008 - October 6, 2008 — The diagnostic utility of flow cytometry has significantly improved over the past decade, and these advances have made it possible to simultaneously measure the cell type and signaling abnormalities that occur as a result of gene...